OOIR: Observatory of International Research

Papers

(The TQCC of Hematological Oncology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
CLINICAL OUTCOMES OF RELAPSED HODGKIN LYMPHOMA PATIENTS AFTER CONTEMPORARY FIRST‐LINE TREATMENT: RESULTS FROM THE GERMAN HODGKIN STUDY GROUP	63
A CONTINUOUS INDIVIDUALIZED RISK INDEX FOR REFINED OUTCOME PREDICTION AFTER TARGETED THERAPY FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CIRI‐CLL)	52
THE POTENTIAL EFFICACY AND MECHANISM OF BENDAMUSTINE IN ENTRA‐NODAL NK/T CELL LYMPHOMA	35
A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15‐YEAR FOLLOW‐UP OF PHASE III SWOG‐S0016	33
	28
PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE PLUS RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA – LOTIS‐5	28
CHARACTERIZATION OF CANCER ASSOCIATED FIBROBLASTS IN CLASSICAL HODGKIN LYMPHOMA	27
Proteomic profiling differentiates classic Hodgkin lymphoma with and without skeletal involvement at the time of diagnosis	26
Regulatory approvals and survival benefit for novel lymphoma drugs from 2013–2022	26
A PHASE I STUDY OF SPLIT‐COURSE BRIDGING RADIOTHERAPY (SC‐BRT) PRIOR TO COMMERCIAL CD19 CAR T‐CELL THERAPIES FOR PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL LYMPHOMAS	25
REAL‐WORLD DURATION OF VENETOCLAX TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA	24
CAR‐T CELLS RADICALLY MODIFY THE MANAGEMENT OF RELAPSED/REFRACTORY PRIMARY CEREBRAL LYMPHOMAS. REAL LIFE RESULTS OF THE FRENCH LOC NETWORK	23
PHASE 1B OPEN‐LABEL STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA (LOTIS‐7)	22
BTK Degradation as a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Preclinical including Patient‐Derived Models	22
Matching‐adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)	22
Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma	21
QUALITY OF LIFE IN PEDIATRIC HIGH‐RISK HODGKIN LYMPHOMA TREATED WITH BRENTUXIMAB‐BASED INTENSIVE CHEMOTHERAPY—COMPARISON TO HISTORICAL TREATMENT COHORT AND HEALTHY PEERS	21
AFM13 IN PATIENTS WITH CD30 POSITIVE RELAPSED OR REFRACTORY (R/R) PERIPHERAL T CELL LYMPHOMA (PTCL): RESULTS FROM THE PHASE 2 REDIRECT STUDY	21
Molecular features possessed in the ctDNA reveal heterogeneity and predict outcome in newly diagnosed peripheral T‐cell lymphoma	21
ENHANCER RNAS (ERNAS) PLAY A ROLE IN THE RESPONSE TO SMALL MOLECULES AND IN THE DEVELOPMENT OF ACQUIRED RESISTANCE IN MARGINAL ZONE LYMPHOMA (MZL)	20
PHASE 1 TRIAL OF KT‐413, A DEGRADER OF IRAK4 AND IMID SUBSTRATES, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMAS	20
EFFICACY OF FRONT‐LINE IMMUNOCHEMOTHERAPY FOR TRANSPLANT‐INELIGIBLE MANTLE CELL LYMPHOMA: A NETWORK META‐ANALYSIS OF RANDOMIZED CONTROLLED TRIALS	20
Brentuximab Vedotin‐Nivolumab alone and then with Rituximab‐Cyclophosphamide‐Doxorubicin‐Prednisone as Frontline Therapy of Primary Mediastinal Large B‐cell Lymphoma	19
MINIMAL RESIDUAL DISEASE STATUS IMPROVED THE RESPONSE EVALUATION IN PATIENTS WITH WALDENSTRöM’S MACROGLOBULINEMIA	19
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia	18

Prognostic impact of complex karyotype on post‐transplant outcomes of myelofibrosis	18
Impact of COVID‐19 infection on bispecific antibodies treatment in patients diagnosed with B‐cell lymphoproliferative disorders	18
Predictors of ibrutinib‐associated atrial fibrillation: 5‐year follow‐up of a prospective study	17
Ibrutinib combined with low‐dose histone deacetylases inhibitor chidamide synergistically enhances the anti‐tumor effect in B‐cell lymphoma	17
A comprehensive analysis of coagulopathy during anti‐B cell maturation antigen chimeric antigen receptor‐T therapy in multiple myeloma, a retrospective study based on LEGEND‐2	17
Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B‐Cell lymphoma ‐results of a single center, retrospective	16
Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis	16
A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma—Outcomes indicative for improved survival overtime	16
Targeting MYC and BCL2 by a natural compound for “double‐hit” lymphoma	16
A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non‐Hodgkin lymphoma	15
How receptor tyrosine kinase‐like orphan receptor 1 meets its partners in chronic lymphocytic leukemia	15
Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions	15
Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax	15
New insights into the Bortezomib‐induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model	15
Safety of acalabrutinib treatment in very old (≥80 y) and/or frail patients with chronic lymphocytic leukemia ‐ interim safety analysis of the ongoing phase II CLL‐Frail trial	15
A PHASE II TRIAL OF REDUCED DOSE BRENTUXIMAB VEDOTIN FOR CUTANEOUS T‐CELL LYMPHOMAS	14
Issue Information	14
HIGH RISK AGGRESSIVE B‐CELL LYMPHOMA ON THE LIQUID BIOPSY	13
THE PATIENT AND CARER EXPERIENCE OF CHIMERIC ANTIGEN RECEPTOR T‐CELL THERAPY FOR RELAPSED/REFRACTORY B‐CELL LYMPHOMA AT A UK REGIONAL CENTRE	13
CLINICAL CHARACTERISTICS AND OUTCOMES OF WALDENSTRÖM MACROGLOBULINEMIA PATIENTS, TREATED AND FOLLOWED IN A PUBLIC BRAZILIAN CENTER	13
SYNERGISTIC ANTICANCER EFFECT OF COMBINED CHIDAMIDE AND ETOPOSIDE TREATMENT AGAINST NK/T CELL LYMPHOMA	13
ENDPOINTS IN MARGINAL ZONE LYMPHOMAS: A SYSTEMATIC REVIEW REVEALS WIDE HETEROGENEITY ACROSS TRIALS AND CALLS FOR STANDARDIZATION	13
AMAHRELIS : ADCETRIS MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN HODGKIN LYMPHOMA : A REAL LIFE STUDY FROM SFGMTC AND LYSA GROUPS	13
TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA: CLINICO‐BIOLOGICAL CHARACTERIZATION, EVALUATION OF TREATMENT RESPONSE AND SURVIVAL	13
LONG TERM OUTCOMES OF GASTRIC MALT LYMPHOMA TREATED WITH RADIOTHERAPY: A MULTI‐CENTRE RETROSPECTIVE STUDY	13
SAFETY AND EFFICACY OF TISAGENLECLEUCEL PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: UPDATED ANALYSIS OF THE PHASE 1B PORTIA STUDY	13
ARTIFICIAL INTELLIGENCE AND MEDICINE: PAST AND FUTURE	12
MR‐GUIDED ADAPTIVE RADIOTHERAPY FOR GASTRIC LYMPHOMA, PRELIMINARY RESULTS FROM ONGOING STUDY	12
Association of cesarean section with risk of childhood leukemia: A meta‐analysis from an observational study	12
Outcomes of hematopoietic cell transplantation for transformed follicular lymphoma	12
A PHASE 1, MULTICENTER, OPEN‐LABEL STUDY OF CC‐99282 ALONE AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMAS	12
Clinical analysis of patients with primary and secondary extranodal natural killer/T‐cell lymphoma of central nervous system	12
Overcoming resistance to anti‐CD19 CAR T‐cell therapy in B‐cell malignancies	12
Primary Mediastinal B‐cell Lymphoma, a nationwide real‐life retrospective study from Fondazione Italiana Linfomi (FIL)	12
BASELINE PET RADIOMICS OUTPERFORMS CLINICAL RISK SCORES IN PREDICTING PRIMARY MEDIASTINAL B‐CELL LYMPHOMA OUTCOME: INSIGHTS FROM THE IELSG37 STUDY	12
Outcome of older myeloma patients in relationship to comorbidities and availability of second‐generation novel agents in a real‐life setting	12
Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL‐102): A phase 1 study	11
Real‐life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience	11
Early granulocyte colony stimulating factor administration increases the risk of cytokine release syndrome in acute lymphoblastic leukemia patients receiving anti‐CD19 chimeric antigen receptor T‐cell	11
IMMUNE PROFILE IN THE PERIPHERAL BLOOD (PB) OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AT DIAGNOSIS AND UPON RELAPSE	11
FLT3‐ITD regulation of the endoplasmic reticulum functions in acute myeloid leukemia	11
Promising clinical efficacy and acceptable safety profile of sequential P‐GEMOX and radiotherapy for localized ENKTL	11
Assessment of Helicobacter pylori (HP) negative gastric MALT lymphoma for non‐H.pylori Helicobacter using multiplex PCR: a retrospective analysis	10
ELUCIDATING THE MOLECULAR MECHANISMS OF CLONAL EVOLUTION IN MULTIPLE MYELOMA THROUGH SINGLE‐CELL RNA SEQUENCING	10
TESTICULAR LARGE B‐CELL LYMPHOMA IS GENETICALLY SIMILAR TO PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA AND DISTINCT FROM NODAL DIFFUSE LARGE B‐CELL LYMPHOMA	10
Deregulated hsa‐miR‐23a‐3p and hsa‐mir‐148a‐3p influence key processes in classic Hodgkin lymphoma (cHL) pathogenesis	10
S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL	10
PROGNOSTIC SCORING SYSTEMS FOR SEVERE CRS AND ICANS AFTER AUTOLOGOUS ANTI‐CD19 CAR T CELLS IN LARGE B‐CELL LYMPHOMA: A DESCAR‐T REGISTRY STUDY FORM THE LYSA	10
Treatment with anti CD19 CAR‐T cells is safe and effective in patients with relapsed refractory large B‐cell lymphoma with active central nervous system involvement	10
CHROMATIN ACCESSIBILITY PROFILING TO INCREASE DIAGNOSTIC ACCURACY AND REFINE CELL‐OF‐ORIGIN CLASSIFICATION OF MATURE T‐CELL LYMPHOMAS	10

Interaction between gut microbiome and immune checkpoint inhibitor treatment in lymphoma patients: Final results of the MICRO‐LINF study	10
INVESTIGATING THE SAFETY AND EFFICACY OF IV FENTANYL FOR BROWN FAT MITIGATION IN ¹⁸FDG‐PET/CT IN PEDIATRIC ONCOLOGY: A MULTI‐INSTITUTIONAL EXPERIENCE	10
LYMPHOMA TISSUE EXPLANTS TO ANTICIPATE RESPONSE TO TARGETED THERAPIES	10
BRCA1/2 MUTATIONS IMPACT ON THE DEVELOPMENT OF BREAST IMPLANT‐ASSOCIATED LYMPHOMA (BIA‐ALCL) IN WOMEN WITH BREAST CANCER RECONSTRUCTED WITH TEXTURED BREAST IMPLANTS	10
A PREDICTIVE MODEL FOR ULTRA‐HIGH RISK IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A SINGLE‐CENTER STUDY IN CHINA	10
EPIGENETIC REGULATION OF IMMUNE MICROENVIRONMENT INTERACTIONS IN LYMPHOMA	10
NATHALI‐01: A PHASE 1/2A TRIAL OF UCART20X22, AN ALLOGENEIC DUAL CAR T‐CELL THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA (NHL)	9
Toxicity and Tolerability of the OEPA/COPDAC Regimen in Children and Adolescents With Hodgkin Lymphoma: A Real‐World Experience	9
Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: 14‐Year Experience of an Academic Center	9
CONCURRENT COMPOSITE LYMPHOMAS COLLECTIVELY BEARING THREE DIAGNOSTIC ENTITIES OF SHARED CLONAL ORIGIN	9
COMBINING BASELINE TOTAL METABOLIC TUMOR VOLUME AND BETA‐2‐MICROGLOBULIN LEVELS PREDICTS OUTCOMES IN HIGH BURDEN FOLLICULAR LYMPHOMA	9
HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA USING REAL‐WORLD DATA FROM FIVE COUNTRIES	9
HIGH COMPLETE RESPONSE RATE WITH TNB‐486, A NOVEL CD19XCD3 T‐CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY	9
Baseline, Drug‐Related and Persistent Anemia and/or Thrombocytopenia Predict Responses and Prognosis in Myelofibrosis Patients Treated With Ruxolitinib	9
Allogeneic transplantation in T‐cell lymphoma: Lessons from the AATT study	9
Remote Monitoring of CAR T‐Cell Treated Patients by a Specialized Nurse to Detect and Manage Late Complications: Report of the CARAMA Program	9
TUESDAY, 13 JUNE 2023 FROM 16:30 TO 18:00 CEST (ROOM B2)	9
BENDAMUSTINE, RITUXIMAB, AND POLATUZUMAB VEDOTIN FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: SINGLE‐CENTER REAL‐WORLD EXPERIENCE	9
A REAL‐WORLD STUDY OF CHIDAMIDE FOR PATIENTS WITH PERIPHERAL T‐CELL LYMPHOMA IN CHINA	9
PROMISING CLINICAL DATA FROM DOSE ESCALATION IN A PHASE IB/II ONGOING STUDY OF MOSUNETUZUMAB WITH POLATUZUMAB VEDOTIN FOR RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMA	9
EXTRANODAL DISEASE IS ASSOCIATED WITH SHORTER PROGRESSION‐FREE SURVIVAL AFTER CD19‐CAR T‐CELL THERAPY FOR RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA	9
Issue Information	9
EFFICACY AND SAFETY OF BTK INHIBITORS IN VITREORETINAL LYMPHOMA: A SINGLE‐CENTER RETROSPECTIVE ANALYSIS OF 24 PATIENTS	9
Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score‐matched analysis	9
Ultrasonography‐guided core‐needle biopsy of lymphadenopathies suspected of lymphoma: Analysis on diagnostic efficacy and safety of 1000 front‐line biopsies in a multicenter Italian study	9
COMPARATIVE EFFICACY OF TISAGENLECLEUCEL (TISA‐CEL) AND LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL)	9
THE SURVIVAL OF 2852 PATIENTS WITH LYMPHOMA: A SINGLE CENTER STUDY FROM CHINA	9
Pola‐R‐CHP versus R‐CHOEP in young patients with high‐risk diffuse large B‐cell lymphoma	9
IN VITRO ANALYSIS PREDICTS CLINICAL RESPONSE OF B CELL LYMPHATIC MALIGNANCIES TO CD19 CAR‐T CELLS: PHENOTYPIC, TRANSCRIPTIONAL AND FUNCTIONAL STUDY	9
LATE TOXICITIES AND LONG‐TERM MONITORING IN CLASSICAL HODGKIN LYMPHOMA AND DIFFUSE LARGE B‐CELL LYMPHOMA SURVIVORS: A SERIES OF SYSTEMATIC REVIEWS OF THE FONDAZIONE ITALIANA LINFOMI	8
PHASE II/III STUDY OF R‐MINICHOP ± ORAL AZACITIDINE IN PARTICIPANTS AGE 75 YEARS OR OLDER WITH DIFFUSE LARGE B CELL AND RELATED LYMPHOMAS	8
Long‐term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in elderly mantle cell lymphoma patients. For the LYSA group.	8
PHASE‐2 FIRST‐IN‐INDIA INDUSTRY STUDY OF VARNIMCABTAGENE AUTOLEUCEL (IMN‐003A) IN RELAPSED REFRACTORY B CELL MALIGNANCIES: IMAGINE STUDY B‐NHL SUBANALYSIS	8
Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype in the RT3 and REMARC trials—A LYSA retrospective analysis	8
Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study	8
Response to SARS‐CoV‐2 vaccination and antibodies persistence in multiple myeloma patients	8
SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA: LONGER FOLLOW‐UP FROM THE PIVOTAL EPCORE NHL‐1 TRIAL	8
Distinguishing myelodysplastic syndromes with moderate‐to‐severe bone marrow fibrosis from triple‐negative primary myelofibrosis based on clinical and genetic covariates	8
Genomic abnormalities involving class I HLA are common in advanced cutaneous T‐cell lymphoma	8
THE ROLE OF CD5+ AS AGGRESSIVE BIOMARKER IN DIFFUSE LARGE B‐CELL LYMPHOMA	8
REAL‐WORLD OUTCOMES WITH NOVEL THERAPIES IN R/R DLBCL	8
Phase 2 study to investigate the efficacy and safety of IMC‐001, anti‐PD‐L1 antibody, in patients with relapsed or refractory extranodal NK/T cell lymphoma, nasal type: DISTINKT Study	8
Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19‐targeted chimeric antigen receptor T‐cell therapy	8
GLOFITAMAB STEP‐UP DOSING: UPDATED EFFICACY DATA SHOW HIGH COMPLETE RESPONSE RATES IN HEAVILY PRETREATED RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL) PATIENTS	8
COMPREHENSIVE ACTIVATION PROFILING OF TABELECLEUCEL, AN OFF‐THE‐SHELF, ALLOGENEIC EBV‐SPECIFIC T‐CELL IMMUNOTHERAPY	8
Baseline PET Total Metabolic Tumor Volume has a prognostic role in PTCLs—Data from International Prospective T‐Cell Project 2.0	8
ORIENT STUDY: REGIMEN OF ORELABRUTINIB PLUS R‐CHOP‐LIKE FOR PATIENTS WITH NEWLY DIAGNOSED UNTREATED NON‐GCB DLBCL	8
Zanbrutinib, lenalidomide plus R‐CHOP (ZR2‐CHOP) as the first‐line treatment for non‐GCB diffuse large B‐cell lymphoma: An updated analysis of efficacy and tolerability	8
The Italian CART‐SIE real life multicenter observational study on Chimeric Antigen Receptor T‐cell (CAR‐T) therapy for large B‐cell (LBCL) and mantle cell (MCL) lymphomas	8
KILT: A RANDOMIZED NON‐COMPARATIVE PHASE II LYSA STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA	8
Issue Information	8
COVID‐19 does not impact on outcome of myeloma patients infected while undergoing autologous stem cell transplantation	8
Metabolic reprograming of exhausted intratumoral CD8+ T‐cell underlies anti‐tumor activity of SUMOylation inhibitors in Large B Cell Lymphoma	8
FOTEMUSTINE‐BASED THERAPY IN COMBINATION WITH RITUXIMAB AS FIRST‐LINE INDUCTION CHEMOTHERAPY FOLLOWED BY WBRT FOR NEWLY DIAGNOSED PCNSL: A PROSPECTIVE PHASE II TRIAL	8
RESEARCH ON COHORT OF PATIENTS RELAPSED ON BRUTON TYROSINE KINASE INHIBITORS (BTKI)	7
DARATUMUMAB AND EPOCH FOR HIV+/‐ PLASMABLASTIC LYMPHOMA: A FEASIBILITY STUDY OF THE AIDS MALIGNANCY CONSORTIUM (AMC 105)	7
Predicting ICANS by means of plasma CAR‐T cell derived extracellular vesicles in patients undergoing infusion of anti‐CD19 CAR‐T cells	7
MATRIX INDUCTION FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT OR WHOLE‐BRAIN IRRADIATION IN PRIMARY CNS LYMPHOMA. 7‐YEAR RESULTS OF THE IELSG32 RANDOMIZED TRIAL	7
A gene expression signature to predict disease progression for Hodgkin Lymphoma patients who achieve a complete metabolic response after 2 ABVD courses	7
TAyloring LYmphoma therapy with Immune Escape Signatures from 3D avatars of B‐cell NHL	7
Overall survival in classic Hodgkin lymphoma pts who progress after autologous stem cell transplant in the era of novel agents	7
Impact of CDA Dynamics on Clinical Outcome of Patients With AML or High‐Risk MDS Treated With Nucleoside Analogs	7
Antibody targeting of surface P‐selectin glycoprotein ligand 1 leads to lymphoma apoptosis and tumorigenesis inhibition	7
Combined single‐cell and spatially‐resolved mapping of lymph node ecosystems reveals principles of lymphoma tissue organization	7
PERIPHERAL T CELL LYMPHOMA (PTCL) AND TREATMENT OUT‐COME SINGLE CENTRE RETROSPECTIVE STUDY	7
POINT‐OF‐CARE ANTI‐BCMA CAR T‐CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH‐RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA	7
Isocitrate dehydrogenase 2 mutation promotes cytarabine resistance in acute myeloid leukemia by Warburg effect	7
VENETOCLAX‐OBINUTUZUMAB MODULATES CLONAL GROWTH: RESULTS OF A POPULATION‐BASED MINIMAL RESIDUAL DISEASE MODEL FROM THE RANDOMIZED CLL14 STUDY	6
COMPARATIVE EFFECTIVENESS OF SALVAGE CHEMOTHERAPY AND CHIMERIC ANTIGEN T‐CELL RECEPTOR THERAPIES IN R/R DLBCL: A SYSTEMATIC REVIEW AND NETWORK META‐ANALYSIS	6
EXTRANODAL NK/T‐CELL LYMPHOMA, NASAL TYPE AND HIV INFECTION: A MEXICAN DESCRIPTIVE SERIES	6
What drives pediatric Burkitt lymphoma? Timing events in the evolution of cancer using single‐cell whole genome sequencing	6
PROGNOSTIC SIGNIFICANCE OF A NOVEL AMINO ACID METABOLIC INDEX IN CHRONIC LYMPHOCYTIC LEUKEMIA	6
Impact of the Affordable Care Act and Medicaid Expansion on Insurance Coverage and Outcomes in Patients with HIV‐associated Aggressive B‐cell Non‐Hodgkin Lymphomas	6
Post‐transplant lymphoproliferative disease in children, adolescents, and young adults	6
STING is Expressed by Hodgkin and Reed Sternberg (HRS) Cells in a Subset of Classical Hodgkin Lymphoma (cHL) and Correlates with Tumor Microenvironment and Immune Response	6
The prognostic value of progressing within 24 months of frontline chemoimmunotherapy (POD24) in relapsed/refractory (R/R) follicular lymphoma (FL)—a SCHOLAR‐5 analysis	6
DISSECTING THE GENETICS OF DIFFERENT ANATOMICAL COMPARTMENTS OF SMALL LYMPHOCYTIC LYMPHOMA WITH A MULTIREGIONAL SEQUENCING APPORACH	6
Liposomal Doxorubicin, Vinblastine and Dacarbazine Plus Consolidation Radiotherapy of Residual Nodal Masses for Frontline Treatment in Older Adults With Advanced Stage Classic Hodgkin Lymphoma: Improv	6
An open‐label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti‐PD‐1 treatment	6
Deciphering the role of MSI2 as a regulator of stem‐like properties in mantle cell lymphoma	6

MINIMAL DISSEMINATED AND MINIMAL RESIDUAL DISEASE IN CHILDHOOD AND ADOLESCENT NON‐HODGKIN LYMPHOMA	6
FIRST‐IN‐HUMAN STUDY OF THE EZH1 AND EZH2 DUAL INHIBITOR VALEMETOSTAT TOSYLATE (DS‐3201B) IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMAS	6
LOW SERUM CHOLESTEROL LEVEL AS A SIGNIFICANT PROGNOSTIC FACTOR IMPROVES CLL‐IPI IN CHRONIC LYMPHOCYTIC LEUKEMIA	6
BIOMARKER‐DRIVEN TREATMENT STRATEGY IN HIGH RISK DIFFUSE LARGE B‐CELL LYMPHOMA: RESULTS OF A NORDIC PHASE 2 STUDY	6
PROTEOMIC PROFILING IDENTIFIES GRANZYME B INHIBITOR SERPIN B9 AS MEDIATOR OF RESISTANCE TO CAR T‐CELL AND BISPECIFIC ANTIBODY TREATMENT IN NODAL B‐CELL LYMPHOMA	6
COPY NUMBER VARIATION ANALYSIS IDENTIFIES DISTINCT GENOMIC FEATURES IN ADULT BURKITT LYMPHOMA	6
16^th International Conference on Malignant Lymphoma Virtual Edition 18 ‐ 22 June, 2021	6
COMBINED MODALITY ULTRA‐LOW‐DOSE ADAPTIVE RADIOTHERAPY AND RITUXIMAB AS TREATMENT STRATEGY FOR INDOLENT NON‐HODGKIN LYMPHOMAS: THE UT SOUTHWESTERN EXPERIENCE	6
Targeting monocytic‐myeloid suppressor cells through CSF1R‐blockade enhances CD19‐CAR T‐cell response in DLBCL	6
Predictors of response to radiation therapy and of progression to multiple myeloma in patients with solitary bone and extramedullary plasmacytomas	6
The role of Vertebral Augmentation Procedures in the management of vertebral compression fractures secondary to multiple myeloma	6
PHASE 2 STUDY OF IBRUTINIB WITH TEMOZOLOMIDE, ETOPOSIDE, LIPOSOMAL DOXORUBICIN, DEXAMETHASONE, RITUXIMAB (TEDDI‐R) FOR SECONDARY CNS LYMPHOMA	6
Real‐world outcomes of brexucabtagene autoleucel (brexu‐cel) for relapsed or refractory mantle cell lymphoma (r/r MCL): A CIBMTR subgroup analysis by prior treatment	6
Deep learning can predict presence of TP53 aberrations and IGHV mutational status from peripheral blood smears of chronic lymphocytic leukemia	6
Characterization of the genetic and epigenetic landscape of B‐cell neoplasms with IG::BCL3‐translocation	6
Demystifying the diagnostic criteria of indolent systemic mastocytosis	5
Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real‐World Data	5
SCIENTIFIC PROGRAM (updated on June 2, 2021)	5
MicroRNAs regulate novel signaling pathways targetable by PI3K, MEK, BCL6 and EZH2 Inhibitors in ibrutinib resistance mantle cell lymphoma	5
PROGNOSTIC VALUE OF METABOLIC PARAMETERS OF BASELINE PET/CT IN PATIENTS WITH DOUBLE EXPRESSION TYPES OF DIFFUSE LARGE B‐CELL LYMPHOMA	5
	5
FIRST REPORT OF THE REAL‐LIFE PROSPECTIVE OBSERVATIONAL STUDY “CAR‐T CELL IN DIFFUSE LARGE B‐CELL AND PRIMARY MEDIASTINAL LYMPHOMAS” OF THE ITALIAN SOCIETY OF HEMATOLOGY	5
VACCINATION STRATEGIES FOR PATIENTS WITH LYMPHOMA: A REAL‐WORLD PRACTICE SURVEY AMONG FONDAZIONE ITALIANA LINFOMI CENTERS	5
Cellular therapy in lymphoma	5
Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia	5
CIRCULATING TUMOR DNA (LIQUID BIOPSY)	5
EARLY PET RESPONSE PREDICTS OUTCOME IN LARGE B‐CELL LYMPHOMA PATIENTS TREATED WITH CD19 CAR‐T	5
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE ERA OF NOVEL THERAPIES‐ A RETROSPECTIVE ANALYSIS BY POLISH LYMPHOMA RESEARCH GROUP	5
MOSUNETUZUMAB MONOTHERAPY IN ELDERLY/UNFIT PTS WITH FIRST‐LINE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): SAFETY AND EFFICACY REMAIN PROMISING WITH DURABLE COMPLETE RESPONSES	5
Efficacy and toxicity of hypofractionated radiation therapy for patients with hematologic malignancies: update on a COVID era ILROG collaborative report	5
NONINVASIVE DETECTION, CLASSIFICATION, AND RISK STRATIFICATION OF PRIMARY CNS LYMPHOMAS BY CTDNA PROFILING	5
Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus‐associated mantle cell lymphoma	5
THE ARCHITECTURE OF LIQUID BIOPSY RESEARCH FOR LYMPHOMA MONITORING	5
VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6‐YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY	5
Central nervous system lymphomas—Assessment and treatment and prevention of central nervous system relapse	5
MARGINAL ZONE LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX (MZL‐IPI): A PROGNOSTIC SCORE FOR THE ENTIRE SPECTRUM OF MARGINAL ZONE LYMPHOMAS. A FIL AND SPORE‐MER STUDY	5
Differential ibrutinib sensitivity in Cd79b‐mutant and wildtype subtypes of a novel Myd88‐driven DLBCL mouse model	5
	5
RELAPSE CHARACTERIZATION IN DIFFUSE LARGE B CELL LYMPHOMA PATIENTS UNDERGOING COMMERCIAL CAR‐T CELL THERAPY: EXPERIENCE FROM A SINGLE CENTRE	5
Comprehensive Analysis of Single‐Cell and Bulk Transcriptomics Identified Regulatory T‐Cell Features as Predictors of Prognosis in Diffuse Large B‐Cell Lymphoma	5
HEALTH‐RELATED QUALITY OF LIFE AMONG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL) IN A PHASE 3 STUDY OF PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN	5
DOSE‐ADJUSTED EPOCH‐RITUXIMAB OR INTENSIFIED B‐NHL‐BFM‐TYPE THERAPY FOR PEDIATRIC PRIMARY MEDIASTINAL B‐CELL LYMPHOMA	5
Early intervention of extracorporeal photopheresis for advancing/progressing cutaneous T‐cell lymphoma	5
Rapid and Sensitive Detection of the MYD88 L265P Mutation for Lymphoplasmocytic Lymphoma/Waldenström's Macroglobulinemia via CRISPR‐Cas12a	5
UNMET NEED IN RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) POST‐BRUTON TYROSINE KINASE INHIBITOR (BTKI): A SYSTEMATIC LITERATURE REVIEW AND META‐ANALYSIS	5
Management of primary and secondary CNS lymphoma	5
UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX+RITUXIMAB RETREATMENT IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): PHASE 3 MURANO SUBSTUDY	5
Long term follow‐up of untreated/relapsing MCL patients with the Ibrutinib, obinutuzumab, and venetoclax combination	5
Primary lymphoma of the female genital tract: a retrospective survey of the International Extranodal Lymphoma Study Group (IELSG35)	5
INFERIOR OUTCOMES WITH POLATUZUMAB VEDOTIN, BENDAMUSTINE AND RITUXIMAB FOR TREATMENT OF RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA AFTER >1 PRIOR LINE OF THERAPY	5
REAL WORLD OUTCOMES AND RESPONSES TO SECOND‐LINE THERAPY IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A MULTICENTRE UK STUDY	5
Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors	5
CLINICAL CHARACTERISTICS AND PATHOLOGICAL DISTRIBUTION IN NON‐HODGKIN LYMPHOMA OF WALDEYER'S RING FROM SINGLE INSTITUTION IN CUBA	5
Subgroup analysis of elderly patients (pts) with diffuse large B‐cell lymphoma (DLBCL) in the Phase 3 POLARIX study	5
Treatment intensification might not improve survival in high‐grade B‐cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: A retrospective, multicenter, pooled a	5
Predictive value on advance hodgkin lymphoma treatment outcome of end‐of treatment FDG PET/CT in the HD0607 clinical trial	5
Enhancing T‐cell responses to GCB‐like lymphomas with immune‐checkpoint‐blockade‐based therapies	4
ELUCIDATING THE ENIGMATIC PATHOBIOLOGY OF HODGKIN LYMPHOMA	4
Combined autologous CD30.CAR‐T cells and nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma after failure of frontline therapy (ACTION study)	4
TIME TO HEMATOLOGIC RECOVERY PREDICTS SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH FLUDARABIN, CYCLOPHOSPHAMIDE AND RITUXIMAB – 11 YEARS OF REAL‐WORLD EXPERIENCE	4
Breaking Traditions: Evaluating Single Fraction Radiation in Indolent Lymphoma	4
Outcomes in patients with EBV+ PTLD treated with allogeneic EBV‐specific T‐cell immunotherapy (tabelecleucel) under an expanded access program (EAP) in Europe	4
TRANSCEND CLL 004: PHASE 1 COHORT OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) COMBINED WITH IBRUTINIB (IBR) FOR PATIENTS (PTS) WITH R/R CLL/SLL	4
Angioimmunoblastic T cell lymphoma prognostic index in Asian population identifies low risk patients with unique gene expression profiles	4
Degradation of CD47‐SIRPα axis by pomalidomide potentiates CD20 antibody‐dependent cellular phagocytosis against B‐cell lymphoma	4
LACUTAMAB IN PATIENTS WITH ADVANCED MYCOSIS FUNGOIDES (MF): EFFICACY RESULTS ACCORDING TO UPDATED LYMPH NODE (LN) CLASSIFICATION IN THE TELLOMAK STUDY	4
COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE AND SHOWS EARLY EFFICACY IN PATIENTS SUFFERING FROM RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA	4
CHRONOS‐3: RANDOMIZED PHASE III STUDY OF COPANLISIB PLUS RITUXIMAB VS RITUXIMAB/PLACEBO IN RELAPSED INDOLENT NON‐HODGKIN LYMPHOMA (INHL)	4
Mature T and NK cell lymphomas classified according to 2016 WHO classification. A report of 741 cases registered in the International Prospective T‐cell Project 2.0.	4
TRAJECTORIES OF LYMPHOMAGENESIS	4
CLONAL ARCHITECTURE OF RELAPSED OR REFRACTORY FOLLICULAR HELPER T‐CELL LYMPHOMA: AN ANCILLARY STUDY OF THE ORACLE TRIAL, A LYSA STUDY	4
25 YEARS OF ANTIBODY TREATMENTS FOR LYMPHOMA	4
Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trials	4
Evaluation of the GELTAMO guidelines for surveillance in follicular lymphomas after first‐line immunochemotherapy: a real‐world prospective study	4
Acalabrutinib in High‐Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real‐Life Experience	4
PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS, SUBGROUP ANALYSIS FROM BRUIN WITH >3 YEARS FOLLOW‐UP FROM START OF ENROLLMENT	4
TRACKING THE EVOLUTION OF UNTREATED HIGH‐INTERMEDIATE/HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMA BY CIRCULATING TUMOR DNA	4
Glofitamab plus immunochemotherapy demonstrates durable efficacy with manageable safety in relapsed/refractory non‐Hodgkin lymphoma (R/R NHL): update of a Phase Ib study	4
TIME‐TO‐RESPONSE FOR PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B CELL NON‐HODGKIN LYMPHOMA TREATED WITH POLATUZUMAB‐BASED THERAPY	4
A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial	4
	4
FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T‐CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION (SGN35‐032, TRIAL IN PROGRESS)	4
Abbreviated whole‐body MRI for follow‐up in pediatric lymphoma: results of a multicenter prospective study	4
DISTINCT HODGKIN LYMPHOMA SUBTYPES IDENTIFIED BY NONINVASIVE GENOMIC PROFILING	4
CLINICAL PRESENTATION, OUTCOME, AND PROGNOSTIC FACTORS IN PATIENTS WITH INTRAVASCULAR LARGE B‐CELL LYMPHOMA: THE ASIA EXPERIENCE FROM A SINGLE‐CENTER RETROSPECTIVE STUDY	4
Outcomes with bendamustine lymphodepletion and brexucabtagene autoleucel for mantle cell lymphoma	4
OUTCOMES OF AUTOLOGOUS TRANSPLANT, ALLOGENEIC TRANSPLANT, AND CAR T CELL THERAPY IN TP53 ALTERED MANTLE CELL LYMPHOMA: A MULTI‐INSTITUTION RETROSPECTIVE ANALYSIS	4
P+R‐ICE: PEMBROLIZUMAB IN COMBINATION WITH R‐ICE CHEMOTHERAPY IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA ‐ ONGOING TRIAL	4
USE OF DEEP LEARNING TO ANALYSE AND EXPLOIT MOLECULAR DATA	4
AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL). REAL‐WORLD REPORT OF POLISH LYMPHOMA RESEARCH GROUP.	4
ACKNOWLEDGEMENTS	4
THE IELSG39 TRIAL: EFFICACY OF FIRST‐LINE CHLAMYDIA PSITTACI ERADICATION WITH A SIX‐MONTH REGIMEN OF DOXYCYCLINE IN PATIENTS WITH STAGE‐I MALT LYMPHOMA OF THE OCULAR ADNEXAE	4
The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation	4
ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT‐NAïVE (TN) CLL/SLL: EXTENDED FOLLOW‐UP OF THE SEQUOIA STUDY	4
EVALUATION OF GONADAL FUNCTION IN YOUNG MEN AND WOMEN DIAGNOSED WITH HODGKIN LYMPHOMA	4